Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: kaltman r. Nat Commun. 2024 May 10;15(1):3957. doi: 10.1038/s41467-024-48359-1. Nat Commun. 2024. PMID: 38730268 Free PMC article. No abstract available.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: kaltman r. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23297559. doi: 10.1101/2023.12.04.23297559. medRxiv. 2023. Update in: Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x PMID: 38105958 Free PMC article. Updated. Preprint.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: kaltman r. Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x. Nat Commun. 2024. PMID: 38538574 Free PMC article. Clinical Trial.
Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
Casasanta N, Kipnis ST, Linville L, Lipinski S, Knoedler A, Marino A, McHenry A, Biagi T, Stark E, Amdur R, Denduluri N, Rodriguez P, Isaacs C, Kaltman R. Casasanta N, et al. Among authors: kaltman r. Clin Breast Cancer. 2020 Apr;20(2):125-130. doi: 10.1016/j.clbc.2019.07.004. Epub 2019 Aug 21. Clin Breast Cancer. 2020. PMID: 31526714
A Life Potentially Saved Through Hereditary Cancer Panel Testing.
Marks D, McHenry A, Biagi T, Stark E, Borum M, Lin P, Kaltman R. Marks D, et al. Among authors: kaltman r. J Oncol Pract. 2017 Apr;13(4):279-281. doi: 10.1200/JOP.2016.016170. Epub 2017 Feb 14. J Oncol Pract. 2017. PMID: 28195815 No abstract available.
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
Anders CK, Woodcock MG, Van Swearingen AED, Moore DT, Sambade MJ, Laurie S, Robeson A, Kolupaev O, Cuaboy LA, Garrett AL, McKinnon K, Cowens K, Bortone D, Calhoun BC, Wilkinson AD, Carey L, Jolly T, Muss H, Reeder-Hayes K, Kaltman R, Jankowitz R, Gudena V, Olajide O, Perou C, Dees EC, Vincent BG, Serody JS. Anders CK, et al. Among authors: kaltman r. J Immunother Cancer. 2022 Feb;10(2):e003427. doi: 10.1136/jitc-2021-003427. J Immunother Cancer. 2022. PMID: 35121644 Free PMC article. Clinical Trial.
14 results